Blackstone Life Sciences

Stories

Blackstone to fund up to $1.5 billion of Pfizer's monthly obesity drug trials

Paying up to $1.5 billion of berobenatide development costs

Pfizer has agreed to let Blackstone Life Sciences pay up to $1.5 billion of the development costs for berobenatide, an experimental weight-loss drug injected once a month. The money covers as many as 10 Phase 3 trials through 2028. Pfizer keeps full control of the program and gives up no ownership of the drug.

Updated 1 hour ago